Dow jumps 360 points on Moderna COVID-19 vaccine news

Dow jumps 360 points on Moderna COVID-19 vaccine news

The Dow and S&P 500 indexes rallied on Monday after Moderna said preliminary trial data showed its COVID-19 vaccine to be 94.5 percent effective – the second promising announcement from the vaccine front in as many weeks.

The Dow Jones Industrial Average vaulted more than 364 points or 1.23 percent at the open of trading on Wall Street, bringing the 30-share index within striking distance of the 30,000 mark.

The broader S&P 500 index – a proxy for the health of US retirement and college savings accounts – jumped 0.76 percent at the open after posting a new record close on Friday.

The Nasdaq Composite Index meanwhile opened virtually unchanged as investors continued to dump Big Tech in favour of shares beaten down by the pandemic.

Shares of Moderna rocketed 10.47 percent in the opening minutes of trading after the biotech firm became the second US company to report positive results from trials of its COVID-19 vaccine candidate.

Last week, Pfizer Inc reported that late-state trial data from the vaccine it is developing with Germany’s BioNTech showed it to be more than 90 percent effective.

The double dose of good news is fuelling hopes that a game-changer is within sight to vanquish the pandemic and put the US and global economies on track for “normalisation”.

“After almost a year in which COVID-19 has ravaged the global economy, there is finally light at the end of the tunnel,” Neil Shearing, Group Chief Economist at Capital Economics, wrote in a Monday note.

Shearing also warned that the current optimism may be short lived as economies grapple with surging infection rates.

“The good news on vaccines is tempered by the fact that they won’t come soon enough to prevent a difficult winter for many economies,” Shearing said.

Infections continue to spike across the United States, with confirmed COVID-19 infections topping the 11 million mark over the weekend, according to Johns Hopkins University.

The wave has ushered in more business-sapping restrictions across the nation as state and local authorities try to contain the spread of the disease.

The United Kingdom, as well as Germany, France and other European nations, have also reintroduced lockdown measures to curb spiralling infections.

Members of Mesa Place Church pray outside University Medical Center of El Paso amid the coronavirus outbreak, in El Paso, Texas, United States [File: Ivan Pierre Aguirre/Reuters]Pfizer’s news last Monday saw investors rotate out of Big Tech and other “stay-at-home” stocks and snap up shares of companies that have been brutalised by the pandemic, such as airlines, financial firms, and cruise and theatre operators.

Among other stocks making headlines on Monday:

Inovio Pharmaceuticals also gained 7.21 percent after getting clearance from the US FDA to begin a mid-stage study of its COVID-19 vaccine candidate.

Shares of Johnson & Johnson were up 0.45 percent after launching a new study to test its own experimental COVID-19 vaccine.

Shares of Simon Property Group Inc, the US’s largest shopping centre operator, jumped 6.84 percent after slashing its purchase price for an 80 percent stake of rival Taubman Centers Inc. The pandemic has decimated the retail industry.